

Christophe Lançon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10813172/publications.pdf>

Version: 2024-02-01

103
papers

2,981
citations

147801

31
h-index

206112

48
g-index

107
all docs

107
docs citations

107
times ranked

3798
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality among inpatients with bipolar disorders and COVID-19: a propensity score matching analysis in a national French cohort study. <i>Psychological Medicine</i> , 2023, 53, 1979-1988.	4.5	5
2	The puzzle of quality of life in schizophrenia: putting the pieces together with the FACE-SZ cohort. <i>Psychological Medicine</i> , 2022, 52, 1501-1508.	4.5	7
3	Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 382-394.	4.3	7
4	Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110479.	4.8	7
5	The Validity of the SQoL-18 in Patients with Bipolar and Depressive Disorders: A Psychometric Study from the PREMIUM Project. <i>Journal of Clinical Medicine</i> , 2022, 11, 743.	2.4	3
6	Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 703-714.	2.6	2
7	Psychometric properties of the BIRT Motivation Questionnaire (BMQ), a self-measure of avolition in individuals with schizophrenia. <i>Journal of Psychiatric Research</i> , 2022, 147, 274-282.	3.1	2
8	Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort. <i>Cognitive Neuropsychiatry</i> , 2022, 27, 49-68.	1.3	2
9	Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, , 1.	3.2	2
10	Effect of Psychiatric Advance Directives Facilitated by Peer Workers on Compulsory Admission Among People With Mental Illness. <i>JAMA Psychiatry</i> , 2022, 79, 752.	11.0	13
11	Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 624-634.	4.3	72
12	Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 298-308.	4.3	45
13	End of life breast cancer care in women with severe mental illnesses. <i>Scientific Reports</i> , 2021, 11, 10167.	3.3	8
14	Outcome prediction with a social cognitive battery: a multicenter longitudinal study. <i>NPJ Schizophrenia</i> , 2021, 7, 30.	3.6	4
15	Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries. <i>JAMA Psychiatry</i> , 2021, 78, 1208.	11.0	155
16	Pregnancy, delivery and neonatal complications in women with schizophrenia: a national population-based cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 10, 100209.	5.6	17
17	Recurrent major depressive disorder's impact on end-of-life care of cancer: A nationwide study. <i>Journal of Affective Disorders</i> , 2020, 263, 326-335.	4.1	8
18	Improving diet for psychiatric patients: High potential benefits and evidence for safety. <i>Journal of Affective Disorders</i> , 2020, 265, 567-569.	4.1	14

#	ARTICLE	IF	CITATIONS
19	Virtual Reality and Fear of Shark Attack: A Case Study for the Treatment of Squalophobia. <i>Clinical Case Studies</i> , 2020, 19, 339-354.	0.8	8
20	<p>Measuring the Patient Experience of Mental Health Care: A Systematic and Critical Review of Patient-Reported Experience Measures</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2147-2161.	1.8	32
21	Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 271, 1571-1578.	3.2	8
22	End-of-Life Care Among Patients With Bipolar Disorder and Cancer: A Nationwide Cohort Study. <i>Psychosomatic Medicine</i> , 2020, 82, 722-732.	2.0	7
23	Microbiota-Orientated Treatments for Major Depression and Schizophrenia. <i>Nutrients</i> , 2020, 12, 1024.	4.1	38
24	Brain PET metabolic substrate of TMS response in pharmaco-resistant depression. <i>Brain Stimulation</i> , 2020, 13, 683-685.	1.6	6
25	The Role of Inflammation in the Treatment of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 160.	2.6	84
26	The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 911-920.	3.2	6
27	End-of-life care among patients with schizophrenia and cancer: a population-based cohort study from the French national hospital database. <i>Lancet Public Health</i> , The, 2019, 4, e583-e591.	10.0	56
28	<p>The Patient-Reported Experience Measure for Improving qUality of care in Mental health (PREMIUM) project in France: study protocol for the development and implementation strategy</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 165-177.	1.8	26
29	Psychiatric advance directives for people living with schizophrenia, bipolar I disorders, or schizoaffective disorders: Study protocol for a randomized controlled trial “ DAiP study. <i>BMC Psychiatry</i> , 2019, 19, 422.	2.6	7
30	Burnout in French physicians: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2019, 246, 132-147.	4.1	96
31	Sensory Gating Capacity and Attentional Function in Adults With ADHD: A Preliminary Neurophysiological and Neuropsychological Study. <i>Journal of Attention Disorders</i> , 2019, 23, 1199-1209.	2.6	27
32	Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 62-68.	4.8	14
33	Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder. <i>Clinical Neurology and Neurosurgery</i> , 2018, 170, 34-37.	1.4	15
34	Modernizing quality of life assessment: development of a multidimensional computerized adaptive questionnaire for patients with schizophrenia. <i>Quality of Life Research</i> , 2018, 27, 1041-1054.	3.1	10
35	A Case of Recovery After Delayed Intracranial Hemorrhage After Deep Brain Stimulation for Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2018, 83, e11-e13.	1.3	4
36	Health related quality of life in patients having schizophrenia negative symptoms “ a systematic review. <i>Journal of Market Access & Health Policy</i> , 2018, 6, 1517573.	1.5	8

#	ARTICLE	IF	CITATIONS
37	Toward a transdiagnostic tool to evaluate depressive symptoms across mental disorders: Validation of the Calgary depression rating scale in patients with major depressive disorder. <i>Psychiatry Research</i> , 2018, 268, 68-71.	3.3	6
38	C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 392.	2.6	53
39	Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. <i>British Journal of Psychiatry</i> , 2018, 213, 464-470.	2.8	35
40	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 567-577.	3.2	21
41	A Multilevel Functional Study of a <i>SNAP25</i> At-Risk Variant for Bipolar Disorder and Schizophrenia. <i>Journal of Neuroscience</i> , 2017, 37, 10389-10397.	3.6	29
42	Defining functioning levels in patients with schizophrenia: A combination of a novel clustering method and brain SPECT analysis. <i>Psychiatry Research - Neuroimaging</i> , 2017, 270, 32-38.	1.8	1
43	The development of the SGI-16: a shortened sensory gating deficit and distractibility questionnaire for adults with ADHD. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2017, 9, 179-187.	1.7	5
44	Psychometric properties of the Ruminative Response Scale-short form in a clinical sample of patients with major depressive disorder. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 929-937.	1.8	42
45	Does sensory gating have a protective effect against hallucinatory behavior in schizophrenia?. <i>Clinical Neurophysiology</i> , 2016, 127, 1746-1748.	1.5	13
46	Unmasking Partial Seizure after Deep Brain Stimulation for Treatment-Resistant Depression: A Case Report. <i>Brain Stimulation</i> , 2016, 9, 636-638.	1.6	8
47	MMPI-2 Profile of French Transsexuals: The Role of Sociodemographic and Clinical Factors. A cross-sectional design. <i>Scientific Reports</i> , 2016, 6, 24281.	3.3	12
48	Virtual reality cue exposure for the relapse prevention of tobacco consumption: a study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 96.	1.6	24
49	A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 27-34.	2.0	61
50	Functional brain substrate of quality of life in patients with schizophrenia: A brain SPECT multidimensional analysis. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 67-75.	1.8	5
51	Working Memory Deficit as a Risk Factor for Severe Apathy in Schizophrenia: A 1-Year Longitudinal Study. <i>Schizophrenia Bulletin</i> , 2016, 42, 642-651.	4.3	20
52	Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram. <i>Journal of Market Access & Health Policy</i> , 2015, 3, 26776.	1.5	1
53	Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study. <i>Scientific Reports</i> , 2015, 5, 17650.	3.3	17
54	Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review. <i>Psychiatry Research</i> , 2015, 229, 12-20.	3.3	36

#	ARTICLE	IF	CITATIONS
55	Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia. <i>Psychoneuroendocrinology</i> , 2015, 57, 125-133.	2.7	6
56	How to interpret multidimensional quality of life questionnaires for patients with schizophrenia?. <i>Quality of Life Research</i> , 2015, 24, 2483-2492.	3.1	10
57	Sensory gating in adult with attention-deficit/hyperactivity disorder: Event-evoked potential and perceptual experience reports comparisons with schizophrenia. <i>Biological Psychology</i> , 2015, 107, 16-23.	2.2	32
58	Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. <i>Schizophrenia Research</i> , 2015, 165, 94-96.	2.0	24
59	Effects of Clozapine on Perceptual Abnormalities and Sensory Gating. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 184-187.	1.4	13
60	Perceptual abnormalities related to sensory gating deficit are core symptoms in adults with ADHD. <i>Psychiatry Research</i> , 2015, 230, 357-363.	3.3	29
61	Satisfaction of hospitalized psychiatry patients: why should clinicians care?. <i>Patient Preference and Adherence</i> , 2014, 8, 575.	1.8	23
62	Determinants of patient satisfaction with hospital health care in psychiatry: results based on the SATISPSY-22 questionnaire. <i>Patient Preference and Adherence</i> , 2014, 8, 1457.	1.8	18
63	Authors' reply. <i>British Journal of Psychiatry</i> , 2014, 204, 80-81.	2.8	0
64	Do patients with schizophrenia use prosody to encode contrastive discourse status?. <i>Frontiers in Psychology</i> , 2014, 5, 755.	2.1	9
65	Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: A structural equation modeling approach. <i>Psychoneuroendocrinology</i> , 2014, 50, 95-105.	2.7	22
66	Validation of the French sensory gating inventory: A confirmatory factor analysis. <i>Psychiatry Research</i> , 2014, 220, 1106-1112.	3.3	11
67	Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. <i>Current Medical Research and Opinion</i> , 2014, 30, 2589-2606.	1.9	23
68	Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices. <i>BMC Neurology</i> , 2014, 14, 78.	1.8	12
69	Do schizophrenia patients with low P50-suppression report more perceptual anomalies with the sensory gating inventory?. <i>Schizophrenia Research</i> , 2014, 157, 157-162.	2.0	26
70	Measuring quality of life in patients with schizophrenia:an overview. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 343-349.	1.4	67
71	Systematic Review Reveals Heterogeneity in the Use of the Scale to Assess Unawareness of Mental Disorder (SUMD). <i>Current Psychiatry Reports</i> , 2013, 15, 361.	4.5	15
72	Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale. <i>Comprehensive Psychiatry</i> , 2013, 54, 1016-1022.	3.1	21

#	ARTICLE	IF	CITATIONS
73	Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. <i>Psychiatry Research</i> , 2013, 210, 381-386.	3.3	46
74	Psychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 229.	2.6	47
75	Evaluation of the Housing First program in patients with severe mental disorders in France: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 309.	1.6	38
76	Predict the outcome of depression after rTMS using neuroimaging: Issue of response or non-response?. <i>Brain Stimulation</i> , 2013, 6, 95-96.	1.6	7
77	Maintenance transcranial magnetic stimulation reduces depression relapse: A propensity-adjusted analysis. <i>Journal of Affective Disorders</i> , 2013, 151, 129-135.	4.1	53
78	Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. <i>Schizophrenia Research</i> , 2013, 147, 58-67.	2.0	41
79	Hormonal Therapy Is Associated With Better Self-esteem, Mood, and Quality of Life in Transsexuals. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 996-1000.	1.0	100
80	Mental Disorders among Children and Adolescents Admitted to a French Psychiatric Emergency Service. <i>Emergency Medicine International</i> , 2013, 2013, 1-7.	0.8	16
81	Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2013, 202, 447-453.	2.8	51
82	Toward Meeting the Needs of Homeless People with Schizophrenia: The Validity of Quality of Life Measurement. <i>PLoS ONE</i> , 2013, 8, e79677.	2.5	26
83	Are Cardiovascular Risk Factors Associated with Verbal Learning and Memory Impairment in Patients with Schizophrenia? A Cross-Sectional Study. <i>Cardiovascular Psychiatry and Neurology</i> , 2012, 2012, 1-8.	0.8	11
84	Schizophrenia with preserved insight is associated with increased perfusion of the precuneus. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, 297-304.	2.4	45
85	Quality of life among caregivers of patients with schizophrenia: a cross-cultural comparison of Chilean and French families. <i>BMC Family Practice</i> , 2012, 13, 42.	2.9	57
86	Improvement of health-related quality of life in depression after transcranial magnetic stimulation in a naturalistic trial is associated with decreased perfusion in precuneus. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 87.	2.4	23
87	Equivalent brain SPECT perfusion changes underlying therapeutic efficiency in pharmacoresistant depression using either high-frequency left or low-frequency right prefrontal rTMS. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 364-370.	4.8	21
88	Neurocognition, Insight and Medication Nonadherence in Schizophrenia: A Structural Equation Modeling Approach. <i>PLoS ONE</i> , 2012, 7, e47655.	2.5	36
89	Quality of life among caregivers of individuals with affective disorders. <i>Journal of Affective Disorders</i> , 2012, 136, 660-665.	4.1	70
90	Parieto-temporal alpha EEG band power at baseline as a predictor of antidepressant treatment response with repetitive Transcranial Magnetic Stimulation: A preliminary study. <i>Journal of Affective Disorders</i> , 2012, 137, 156-160.	4.1	56

#	ARTICLE	IF	CITATIONS
91	Is Hormonal Therapy Associated with Better Quality of Life in Transsexuals? A Cross-sectional Study. <i>Journal of Sexual Medicine</i> , 2012, 9, 531-541.	0.6	140
92	Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2012, 202, 155-160.	1.8	25
93	Fiabilité des références diagnostiques du Recueil d'Informations Médicales en Psychiatrie. <i>Santé Publique</i> , 2012, Vol. 23, 31-38.	0.1	8
94	Frequent Visits to a French Psychiatric Emergency Service: Diagnostic Variability in Psychotic Disorders. <i>Psychiatric Services</i> , 2011, 62, 966-970.	2.0	28
95	Predictive value of brain perfusion SPECT for rTMS response in pharmacoresistant depression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1715-1722.	6.4	63
96	Genetic and molecular exploration of UHMK1 in schizophrenic patients. <i>Psychiatric Genetics</i> , 2011, 21, 315-318.	1.1	7
97	The development of the S-QoL 18: A shortened quality of life questionnaire for patients with schizophrenia. <i>Schizophrenia Research</i> , 2010, 121, 241-250.	2.0	101
98	The 4-Point ordinal Alliance Self-report: a self-report questionnaire for assessing therapeutic relationships in routine mental health. <i>Comprehensive Psychiatry</i> , 2009, 50, 181-185.	3.1	31
99	The "Functional Remission of General Schizophrenia" (FROGS) scale: Development and validation of a new questionnaire. <i>Schizophrenia Research</i> , 2009, 113, 218-225.	2.0	95
100	Assessing health-related quality of life in patients suffering from schizophrenia: a comparison of instruments. <i>European Psychiatry</i> , 2005, 20, 510-519.	0.2	36
101	Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. <i>Journal of Psychiatry and Neuroscience</i> , 2002, 27, 30-7.	2.4	37
102	Clozapine and negative symptoms. An open study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2000, 24, 373-384.	4.8	8
103	Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale. <i>Psychiatry Research</i> , 1999, 89, 123-132.	3.3	33